Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — Investor Day (2025)
47 slides from Wuxi Apptec Co., Ltd. Class A's investor day presentation, Nov 9, 2025
Slide 1: Research Enabling Platforms Enhance CRDMO Business Model
2025 WuXi AppTec Investor Day Research Enabling Platforms Enhance CRDMO Business Model Steve Yang, Ph.D. Co-CEO 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Global R&D Pipelines Keep Growing Steadily over Past Years
Global R&D Pipelines Keep Growing Steadily over Past Years Small Molecule Remains the Leading Modality, with Increasing Contributions from New Modalities Global R&D Pipeline by Modality, 2015-2024 40,000 64.8% 65.4% 70 62.2% 62.1% 60.3% 59.6% 57.1% 54.9% 54.9% 54.3% 60 35,000 50 30,000 40 25,000 22,
Slide 4: Steady Growth in Global Pharmaceutical R&D Spending Across the Industry
Steady Growth in Global Pharmaceutical R&D Spending Across the Industry Global Pharmaceutical R&D Spending to Grow at ~6% CAGR (2024-2029E); Large and Mid-size Pharmas Contributing ~80% Today; Small Biopharmas’ Share to Rise from ~20% to ~30% by 2034E with ~9% CAGR Global R&D Spending by Pharma Comp
Slide 5: Diversified Funding Sources in Ecosystem to Ensure Continued R&D Investment
Diversified Funding Sources in Ecosystem to Ensure Continued R&D Investment Despite Some Challenges in Capital Market, H1 2025 has been Strong in Dealmakings (Licensing and M&A) for Biopharmas to Accelerate Pipeline Replenishment Global Biotech Funding Global License Deals Global M&A Deals (IPO + FO
Slide 6: Diversified Modality Demands in Early Stage R&D Investment
Diversified Modality Demands in Early Stage R&D Investment Established Modalities (Small Molecule & Biologics) Continue to Lead, while New Modalities Gain Traction VC Funding by Modality, 2022 - H1 2025 USD billion 5.9% 5.9% 5.9% CGT, 20.4 Oligo, 8.8 Small Molecule, 43.7 Antibody / Protein, 30.0 Pep
Slide 7: Innovators Across Regions Ensure the Continuous Emergence of Innovation
Innovators Across Regions Ensure the Continuous Emergence of Innovation In Addition to US, Europe & China are Important Innovation Hubs, Each with ~50% as Many Companies as US Number of Pharmaceutical Companies by Development Phase # of companies 1,979 1,247 1,027 827 732 718 763 687 561 522 559 566
Slide 8: Scientific Innovations Continue to Generate ~1,000 New Companies Annually
Scientific Innovations Continue to Generate ~1,000 New Companies Annually Large and Mid-size Pharmas Account for ~20%, while Small Biopharmas Gradually Expand to 80%+ Number of Global Pharmaceutical Companies, 2015-2034E 83.4% 83.8% 82.8% 83.1% 82.0% 82.4% 81.2% 81.6% 80.4% 80.8% 80.0% 79.5% 77.6% 7
Slide 9: Global Outsourcing Market Continues to Expand with Increased Innovation
Global Outsourcing Market Continues to Expand with Increased Innovation Contributions from Small Companies and Diversified Demands Global CRO Outsourcing Penetration Exceeding 50% in 2024 and Expected to Reach 65%+ in 2034E Global CRO Outsourcing Rate, 2015-2034E 38.2% 37.0% 36.1% 35.1% 34.4% 42.8%
Slide 10: Global Outsourcing Market Grows Faster than Overall R&D Spending
Global Outsourcing Market Grows Faster than Overall R&D Spending Global Outsourcing Market Growing at 11.9% CAGR 2024-2029E, with Momentum Expected to Continue for Many Years to Come Global Pharmaceutical R&D Outsourcing Market, 2015-2034E 448.4 Small Including: Including: Period Discovery Preclinic
Slide 11: WuXi Chemistry, Biology, and Testing Collaborate at Research Stage
WuXi Chemistry, Biology, and Testing Collaborate at Research Stage to Enhance CRDMO Business Model Generate the Flow Discovery by enabling discovery and research Preclinical Understand the Trends by following science and customers WuXi Chemistry Achieve Synergy through accelerating PCC and IND deliv
Slide 12: Attract New Customers to WuXi AppTec CRDMO Platform
Attract New Customers to WuXi AppTec CRDMO Platform ~70% of WuXi AppTec new customers are supported by Discovery + Preclinical in 2024 of Discovery + Preclinical 2024 new biotech ~35% customers* have public fund raising events after 2019 12 Notes: 1. Including Discovery and Preclinical customers. *
Slide 13: Enhance Customer Engagement through Integrated Services
Enhance Customer Engagement through Integrated Services # of Customers use both Discovery & Preclinical platforms 900+ 1000+ 800+ 2022 2023 2024 74.4% Revenue% of customers 73.2% use both Discovery & 72.4% Preclinical platforms 2022 2023 2024 13 Note: Discovery represents WuXi Biology and RCS (Resea
Slide 14: Small Molecule Market Expansion
Small Molecule Market Expansion ~42% Research Chemistry Services (RCS) synthesized over 440,000+ compounds from 2024H2 to 2025H1 The application of Flow Chemistry and of active customers in market* collaborate with us since 2021 Photochemistry Technologies benefits over 91% of our long-term partners
Slide 15: From Undruggable Targets to Druggable
From Undruggable Targets to Druggable Previously Undruggable New Modalities Targets (e.g. RAS) PROTAC Molecular glue 10+ drugs approved 100+ Multi-Specific Drugs Covalent inhibitor Allosteric inhibitor programs in clinical development Peptide Macrocycle 15 Source: 1. The Biology of Cancer, 2nd editi
Slide 16: Increasing Molecular Complexity
Increasing Molecular Complexity Molecular weight Synthetic steps Synthetic complexity Purification difficulty Proportion of compounds with molecular Average synthesis steps Average molecular weight weight >600 Da for long-route molecules* 26% 16% 2021 2025 2021 2025 2021 2025 16 Source: internal ana
Slide 17: Sophisticated Analytical Platform for Complex Synthetic Molecules
Sophisticated Analytical Platform for Complex Synthetic Molecules Instruments & Workflows Techniques & Capabilities • 1900+ cutting-edge instruments and equipment • Comprehensive coverage of 60+ analysis items Dedicated technical solution for new • Automated streamline workflows (1h cycle time for m
Slide 18: Advancing Drug Discovery & Development of "Undruggable Targets"
Advancing Drug Discovery & Development of “Undruggable Targets” Supporting Mirati Therapeutics Financing in the discovery & development of on the ‘undruggable' KRAS Target therapies for undruggable targets from 2022 to 2024 “WuXi AppTec has been one of our longest standing partners with whom we work
Slide 19: Value and Contribution of WuXi AppTec Research Chemistry Service (RCS)
Value and Contribution of WuXi AppTec Research Chemistry Service (RCS) Accelerating PCC Finding Contributing to Customer Success Average time to identify a of small molecules deals 13.7 months PCC after collaborating 60% (>$100M) come from RCS with RCS partners in past 3 years Produced within RCS 10
Slide 20: Continue to Strengthen the Conversion from R to D
Continue to Strengthen the Conversion from R to D • Understand potential requirements and “R” 1,000+ provide specific solutions Active clients • Work closely between R and D teams • Ensure consistent high-quality transition from R to D stages 308 185 “D” Clients with “D” opportunity New clients from
Slide 21: Customer Growth and Retention in Research Chemistry
Customer Growth and Retention in Research Chemistry ≥5 years ≥10 years ≥20 years 980+ clients 280+ clients 10+ clients 21
Slide 22: The Expansion of Biology in vitro Hit Generation & Hit Finding Platform
The Expansion of Biology in vitro Hit Generation & Hit Finding Platform 2010 2025 POD 810 Plate Assembler Versatile, multi-threaded, multi-project parallel high-throughput screening Shanghai Operational Sites Shanghai, San Diego, Munich 20+ Key Instrument # 400+ 22 Note: POD 810 Plate Assembler, for
Slide 23: Industry Leading Platform for Hit Finding
Industry Leading Platform for Hit Finding Track Record of Early Discovery Capabilities • 15+ years of experience • 1800+ clients • 1000+ targets screened • 1500+ proteins produced WuXi Biology High-throughput Hit Finding Technologies Integrated solution for successful hit finding with all target cla
Slide 24: Capability Building Flywheel for Oncology
Capability Building Flywheel for Oncology 2017-2024 CAGR 38% End-to-end services and •System •Standard solutions to enable cancer ~33% •Process drug discovery • 1,200+ cell lines and 4,000+ disease models •Capability of active customers in market* Project •Technology • 19,000+ cancer pharmacology co
Slide 25: Infectious Disease Market Expansion
Infectious Disease Market Expansion ~27% 21 drugs on >40 types of infectious market agents of active customers in market* collaborate with us since 2021 in vitro screening and profiling in vivo efficacy clinical assay Biology Infectious Disease Platform 25 Notes: 1. Internal analysis. 2. Including D
Slide 26: Biology Non-cancer in vivo Pharmacology Delivered Over 40% YoY Growth
Biology Non-cancer in vivo Pharmacology Delivered Over 40% YoY Growth +42% +115% +7% +31% +98% Non-cancer in vivo Pharmacology Revenue 25 H1 vs 24 H1 Metabolic Immunology & Infectious Neuroscience Disease Inflammation Disease 26 Note: WuXi Biology data only.
Slide 27: In vivo Pharmacology Integration Across Therapeutic Areas
In vivo Pharmacology Integration Across Therapeutic Areas Infectious Disease ~27% •System •Standard •Process Immunology & Inflammation ~35% •Technology Project •Capability Delivery •Know-how Metabolic Disease ~33% •Efficiency •Speed •Quality Neuroscience ~35% 27 Notes: 1. Internal analysis; data rep
Slide 28: Early Capability Building in Emerging Technologies
Early Capability Building in Emerging Technologies Bispecific antibody ADC Target Protein Single-cell Stem cell Oncolytic viruses OBOC DAC Degradation 2015 2019 2021 2023 2014 2016 2020 2022 2024 Cancer vaccine Fusion protein CAR-T / CGT Covalent inhibitor Peptide Early Discovery Oligo Tumor Infiltr
Slide 29: New Modality Market Expansion
New Modality Market Expansion ~29% of active customers in market* collaborate with us since 2021 Achieved 30%+ of Biology 2024 total revenue • Targeted Protein Degradation • Oligo / Antisense • ADC / PDC / AOC • Cancer Vaccine / Oncolytic virus / Stem Cell / Exosomes • Vector Platform/ Novel Drug De
Slide 30: Nucleic Acid Therapeutics Market Expansion
Nucleic Acid Therapeutics Market Expansion Biology Revenue ~26% +26% YOY (2024 vs 2023) Capability and capacity of active customers in market* Quality and turnround time collaborate with us since 2021 Experience Solution provider Nucleic Acid Therapeutics 30 Notes: 1. Internal analysis. 2. Including
Slide 31: Targeted Protein Degrader Market Expansion
Targeted Protein Degrader Market Expansion ~67% of active customers in market* collaborate with us since 2021 Targeted Protein Degrader 31 Notes: 1. Internal analysis. 2. Including Discovery and Preclinical customers. 3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Precli
Slide 32: WuXi Biology - Continuously Bringing New Customers
WuXi Biology - Continuously Bringing New Customers New Customer# New Customer PO Amount 5% 17% 24 H1 25 H1 24 H1 25 H1 32 Note: WuXi Biology data only.
Slide 33: Preclinical Platform Growth
Preclinical Platform Growth Total Space 210,000+ M2 Suzhou | 2024 IND package 1,240 Ongoing Nantong | 2024 IND projects Suzhou | 2008 820+ 33
Slide 34: Drive Preclinical Conversion Through CRDMO Business Model
Drive Preclinical Conversion Through CRDMO Business Model WuXi Testing 1240+ IND projects # conversion WuXi Chemistry 820+ Global Market WuXi Biology Ongoing IND 370+ Joint IND projects # projects # 860+ IND projects # conversion WuXi Testing 410+ IND projects # Enabling study completed Progress to
Slide 35: Preclinical New Orders Value Growth
Preclinical New Orders Value Growth +14.5% +11.6% +30.7% +19.9% CN EU US 24H1 25H1 24H1 25H1 24H1 25H1 24H1 25H1 35 Note: new order growth in terms of contract values.
Slide 36: New Modality Capability and Results in DMPK
New Modality Capability and Results in DMPK Revenue 25 H1 vs 24 H1 CRDMO DMPK PDC Conversion +26% Antibody +60% DMPK Solution Package for New Modality • In vitro metabolism models Peptide • • Animal administration & sampling techniques Integrated bioanalytical platform to support multiple +68% types
Slide 37: New Modality Capability and Results in Bioanalytical Service (BAS)
New Modality Capability and Results in Bioanalytical Service (BAS) Cutting-edge Technology and Comprehensive Capabilities Substantial revenue growth in new modalities Oligo GalNAc-oligo 25 H1 vs 24 H1 ASO Probody CGT Multi-specific PROTAC +393% ADCs Antibodies New Aptamer Modalities CAR-T ADC CRISPR
Slide 38: One-Stop Service Enables Global Licensing and Collaboration
One-Stop Service Enables Global Licensing and Collaboration Case study: Enable global collaboration and licensing of an experimental medicine targeting metabolic disease Enable preclinical and clinical development 40% through end-to-end CRDMO Platform Drug Substance TIDES IND Enabling Drug Product S
Slide 39: Focus on Operational Excellence: WuXi Biology
Focus on Operational Excellence: WuXi Biology Biology Centralized Management Platform Streamlined Centralized Project Standardized Execution Automated Reporting Experimental Planning Tracking & Oversight & Data Capture & Analysis Redefine Delivery Efficiency Strengthen Security & Compliance 32% fast
Slide 40: Focus on Operational Excellence: DMPK
Focus on Operational Excellence: DMPK First Self-developed Software • Algorithmic and automated data processing platforms Efficiency • Automatically recognizes input Tides structures 25 H1 vs 24 H1 • Match MS and MS2 data in one place Improvement in Spectral Resolution +83% Diversified peptide backb
Slide 41: Focus on Operational Excellence: Toxicology
Focus on Operational Excellence: Toxicology Scalable Sales Resource Allocation Quality & Risk Control Customer Success 3,200+ 25,000+ Powered by Served Clients Delivered Orders real-time data and advanced algorithms Coverage Planning Accuracy 56.4% 55.8% 24 FY vs 23 FY 24 FY vs 23 FY Overall Labor A
Slide 42: Focus on Operational Excellence: Bioanalytical Service
Focus on Operational Excellence: Bioanalytical Service E-Platform and Automation to Enhance Efficiency Efficiency Quality Data Security 25 H1 vs 24 H1 Project Turnaround Time Reduction 30% Analytical Time Reduction 35% Hamilton Gyrolab Tecan Simoa KingFisher 42
Slide 43: Maintain the Highest Global Regulatory Standards
Maintain the Highest Global Regulatory Standards Audit AAALAC BSL-2 120,000 m2 • 11 Regulatory agencies GLP Facility • 217 Customers GLP NMPA Meeting Global Quality Standard 43 Note: data from H2 2024 to H1 2025.
Slide 44: Achieve Customer Satisfaction and Maintain High Retention Rates
Achieve Customer Satisfaction and Maintain High Retention Rates 98% 98% Empower Customers Enable Innovation 98% 2025H1 Build Trust 97% 2024 2023 2022 TOP 300 70%+ revenue contributor 44 Note: TOP 300 WuXi Discovery + Preclinical customers.
Slide 45: Continued Increase in Number of Active Customers Worldwide
Continued Increase in Number of Active Customers Worldwide -0.4% +3.9% +3.6% North America EU Asia & Others 24 FY vs 23 FY 24 FY vs 23 FY 24 FY vs 23 FY 23 FY 24 FY 23 FY 24 FY 23 FY 24 FY 45 Notes: 1. Data represent YoY growth % of active customers. 2. Including Discovery and Preclinical customers.
Slide 46: Integrated Research Platform Enabling CRDMO Business Model
Integrated Research Platform Enabling CRDMO Business Model, One-Stop Solution at WuXi AppTec WuXi Chemistry WuXi Biology WuXi Testing WuXi Biology Med Chem, Hit Finding ADME / PK Synthesis and Hit to Lead TOX Manufacturing Lead Optimization IND-Enabling Package ——————————————— WuXi AppTec ——————————
Slide 47: July 17, 2000 May 28, 2001 >10 X
July 17, 2000 May 28, 2001 >10 X 47